The company published data for the bispecific antibody in wet AMD and DME, with non-inferior efficacy to Eylea and growing support for less frequent administration.

When almost everything that could go wrong has gone wrong at a company, the proposition of it turning acquirer may meet with some resistance from its proposed targets and their investors.

Gene therapies for conditions ranging from hemophilia to retinal diseases are blossoming in China and the race in which the winner may take all is on. Driven by ready investors, the field is on the cusp of becoming the latest innovation battleground in the country, while some developers are already moving ahead in the US.

Lupin’s partnership with Shenzhen Foncoo marks the Indian firm's much-awaited entry into China. Will this and more planned alliances make Lupin a worthy respiratory challenger to AstraZeneca, compatriot Cipla and others in a country where chronic respiratory diseases are the second leading cause of death?